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A B S T R A C T
In this study, we aimed to evaluate the cytotoxic and apoptotic effects of zoledronic acid on K562 chronic
myeloid leukemia (CML) cells and to examine the roles of STAT genes on zoledronic acid-induced
apoptosis. The results showed that zoledronic acid decreased proliferation, and induced apoptosis in
K562 cells in a dose- and time-dependent manner. mRNA and protein levels of STAT3, -5A and -5B genes
were significantly reduced in zoledronic acid-treated K562 cells. These data indicated that STAT
inhibition by zoledronic acid may be therapeutic in CML patients following the confirmation with clinical
studies.
 2013 Elsevier Masson SAS. All rights reserved.
Available online at
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Chronic myeloid leukemia (CML) is a malignant disorder of the
haematopoietic stem cell arisen from the reciprocal translocation
between the breakpoint cluster region (BCR) gene on chromosome
22, and the Abelson (ABL) murine leukemia virus gene on
chromosome 9, t(9;22)(q34;q11), resulting in the formation of
Philadelphia (Ph) chromosome. Ph chromosome encodes the BCR–
ABL fusion protein, which has constitutive tyrosine kinase activity,
leading to leukemogenesis [1]. Imatinib mesylate, a selective
inhibitor of the ABL tyrosine kinase, has demonstrated a remarkable
efficacy in the treatment of CML by inducing cytogenetic remissions
in over 75% of chronic phase patients, as the first line therapy [2].
However, drug-resistance and early relapses frequently occur in a
considerable proportion of patients, as the main limitation for a
prolonged survival [3]. Resistance to imatinib is caused primarily by
point mutations in the kinase domain of BCR–ABL, which block drug
binding [4]. To overcome this problem, more selective second
generation ABL tyrosine kinases have been developed, but
unfortunately, there is still a group of patients that fail to achieve
sustained responses [5–7]. Therefore, new therapeutic approaches
are being recently investigated in order to overcome the resistance
problem and targeting the alternative downstream regulators of
BCR–ABL seems promising.* Corresponding author. Tel.: +90 232 7507515; fax: +90 232 7507509.
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http://dx.doi.org/10.1016/j.biopha.2013.04.006It is known that BCR–ABL activates multiple signalling
pathways, including rat sarcoma (Ras), myelocytomatosis
(Myc), Janus kinase/signal transducers and activator of transcrip-
tion (JAK/STAT) and Phosphoinositide 3-kinase/Akt (PI3K/Akt)
that lead to uncontrolled proliferation and inhibition of apoptosis.
Since the critical role of JAK/STAT pathway has been demon-
strated in myeloid differentiation, novel therapeutic strategies
have remarkably focused on targeting this pathway. STAT
proteins are a family of latent cytoplasmic transcription factors
that are involved in several cellular processes, such as prolifera-
tion, survival, apoptosis, and differentiation [8]. Constitutive or
aberrant activation of STATs was hypothesized to cause cellular
transformation, and in particular, leukemogenesis [9,10]. Seven
mammalian STAT proteins have been discovered: STAT1 to -4,
STAT5A, STAT5B, and STAT6 [11]. STAT1, -3 and -5 contribute to
the progression or suppression of malignant transformation.
STAT1, the first STAT to be discovered, is required in innate
immunity, and has a tumour-suppressive role in oncogenesis as it
mediates growth inhibitory signals and promotes apoptosis. It
also contributes to the host rejection of tumours [12,13].
Inhibition of STAT3 pathway has been shown to induce apoptosis
in cancerous cells by down-regulating the expressions levels of
antiapoptotic B-cell lymphoma-extra large (Bcl-XL) and myeloid
cell leukemia-1 (Mcl-1) genes [14,15]. Increased or unrestrained
JAK2, platelet-derived growth factor receptor (PDGF-R), or ABL
signaling by the expression of fusion proteins was shown to cause
constitutive activation of STAT5, which is effective in the
development of malignancy [13].
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potent inhibitor of osteoclast-mediated bone resorption, and it is
primarily established in the management of metastatic bone
disease. Accumulating preclinical data has suggested that zole-
dronic acid has also remarkable anticancer activities in a variety of
solid and haematological malignancies [16–19]. Beside its direct
anticancer effects like reducing proliferation and inducing
apoptosis, it has also indirect effects like activating anticancer
immune responses, inhibiting angiogenesis, and inhibiting inter-
actions with mesenchymal stem cells [20–22]. It was shown that
zoledronic acid inhibits the activation of Ras proteins through the
suppression of both farnesyl transferase and geranylgeranyl
transferase enzymes within the mevalonate pathway. These
enzymes are essential for the prenylation of Ras proteins, and
blocking prenylation results in reduced cellular growth and
proliferation with induced apoptosis of cancer cells [23]. Ras is a
major downstream signal transducer of BCR–ABL and on this basis,
it has been demonstrated that zoledronic acid has a considerable
antileukemic activity in CML cell lines and mouse models [24].
Furthermore, recent evidence suggests that there is a variety of
anticancer mechanisms, which have been attributed to the action
of zoledronic acid, and it is important to clarify the exact
underlying mechanisms in order to determine the future antic-
ancer strategies.
In this study, we aimed to evaluate the cytotoxic and apoptotic
effects of zoledronic acid on human K562 CML cells and to clarify
the roles of STATs on zoledronic acid-induced apoptosis.
2. Materials and methods
2.1. Cell line, culture conditions and chemicals
K562 CML cells were kindly provided by Dr. Serdar Bedii Omay
from Ege University. K562 cells were grown in RPMI 1640 medium
(Kibutz Beit Haemeh, Israel), containing 10% foetal bovine serum
(FBS) (Life Technologies, Grand Island, NY, USA) and 1% penicillin–
streptomycin were maintained in a standard cell culture incubator
at 37 8C in 5% CO2. Zoledronic acid was obtained from Novartis
Pharma (Basel, Switzerland). Trypan blue dye was obtained from
Sigma Chemical (St. Louis, MO, USA). 2,3-Bis[2-methoxy-4-nitro-5-
sulphophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT).
Cell Proliferation Assay was obtained from Biological Industries
(Israel). AnnexinV-EGFP Apoptosis Detection Kit was obtained
from Biovision (CA, USA). All the other chemicals and tissue culture
supplies were obtained from Sigma Chemical unless otherwise
specified.
2.2. Measurement of cytotoxicity
Cytotoxicity assay and determination of the concentration of
zoledronic acid that inhibits cell proliferation by 50% (IC50) were
performed by XTT cell proliferation assay (Biological Industries,
Israel) as indicated in the manufacturer’s instructions. Briefly,
1  104 K562 cells were plated into 96-well plates containing
100 mL of the growth medium in the absence or presence of
increasing concentrations of zoledronic acid and incubated at 37 8C
in 5% CO2. After 24, 48, 72 and 96 h incubation, cells were treated
with 50 mL XTT solution for 4 h and then, the plates were read under
492 nm wavelength by ELISA reader. Finally, the IC50 dose of
zoledronic acid was calculated from the cell proliferation plots [25].
2.3. Evaluation of apoptosis
Zoledronic acid-induced apoptosis of K562 cells was evaluated
by fluorescence microscopy using AnnexinV-EGFP ApoptosisDetection Kit (Biovision) as described in the manufacturer’s
instructions. In short, K562 cells were treated with 60 mM of
zoledronic acid and apoptosis was induced. At 0, 24, 48, 72 and
96 h time points, 5  105 cells were collected and 500 mL 1x
binding buffer was added to the cell suspension. Subsequently,
5 mL annexinV-EGFP and 5 mL propidium iodide (PI) were added,
and the cells were incubated in the dark for 5 min at room
temperature. Consequently, the cells were transferred onto a cover
glass and morphologically examined by fluorescence microscopy.
2.4. Total RNA Isolation and quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR)
Total RNA was isolated from K562 cells treated with 60 mM of
zoledronic acid at 24, 48, 72 and 96 h post-incubation using High
Pure RNA Isolation Kit (Roche Applied Science, Mannheim,
Germany) as described by the manufacturer. One microgram of
total RNA was reverse transcribed using Transcriptor High Fidelity
cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany)
in accordance with the instructions provided by the manufacturer.
After 1 h incubation at 37 8C, the reaction was stopped at 65 8C for
10 min. The resulting total cDNAs were then used to determine the
mRNA levels of STAT3, STAT5A, and STAT5B. Q-PCR was performed
with gene-specific primers and probes using the Fast Start DNA
Master Hybridisation Probes (Roche Applied Science, Penzberg,
Upper Bavaria, Germany) and Glucose-6-phosphate dehydrogen-
ase (G6PDH) House Keeping Gene Kit (Roche Applied Science,
Mannheim, Germany). G6PDH gene was used as an internal
positive control in all PCR reactions, and its amplification product
provided both a control for PCR performance and a reference for
quantification of PCR products. The primer sequences were
(TibMolBiol, Berlin, Germany): STAT3-F: 50-ACCAACAATCCCAA-
GAATGT-30, STAT3-R: 50-CGATGCTCAGTCCTCGC-30; STAT5A-F: 50-
GAAGCTGAACGTGCACATGAATC-30, STAT5A-R: 50-GTAGGGACA-
GAGTCTTCACCTGG-30; STAT5B-F: 50-AGTTTGATTCTCAGGAAA-
GAATGT-30, STAT5B-R: 50-TCCATCAACAGCTTTAGCAGT-30. Two
microlitres of the reverse transcriptase reaction was amplified
using these primers for 50 cycles (95 8C, 10 s; 56 8C, 10 s; 72 8C,
5 s). The mRNA levels of STAT3, -5A, and -5B were determined in a
Real-Time Light Cycler Instrument (Roche Applied Science). The
relative expression level for each gene was calculated by dividing
the mRNA copy number of the target gene by the G6PDH mRNA
copy number of the reference gene.
2.5. Western blot analysis
Protein levels of STAT3, STAT5A, STAT5B and b-actin, an
internal positive control, genes were detected by Western blot
analysis. For protein extraction; the cells were lysed by using
ProteoJET Mammalian Cell Lysis Reagent (Fermentas, Maryland,
USA), and subsequently incubated for 10 min on ice. Nuclei were
removed by centrifugation at 20,000xg for 15 min, and the cell
lysates were assayed for protein contents using the Bradford
protein assay. Protein samples were separated by running on 8%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) (Bio-Rad, Richmond, CA, USA), and then transferred onto a
PVDF membrane. The primary antibodies used for immunblotting
were anti-STAT3 (1:1000, rabbit polyclonal IgG, Upstate-Cell
Signalling Solutions, Lake Placid, NY, USA), anti-STAT5A (1:2000,
rabbit antiserum, Upstate-Cell Signalling Solutions), anti-STAT5B
(1:2000, rabbit antiserum, Upstate-Cell Signalling Solutions) and
anti-b-actin (1:1000, Cell Signalling Technology, Danvers, MA,
USA). The protein levels of target genes in each fraction were
detected by using the enhanced colorimetric detection kit
(Amplified Alkaline Phosphatase Goat Anti-Rabbit Immune-Blot
Assay Kit, Bio-Rad) according to the manufacturer’s instructions.
Fig. 1. Cytotoxic effects of zoledronic acid on K562 chronic myeloid leukemia cells.
The concentration of zoledronic acid that inhibited cell growth by 50% (IC50) was
calculated from cell proliferation plots. The XTT assays were performed using
duplicate samples in at least two independent experiments. The error bars
represent the standard deviations, and when not seen, they are smaller than the
thickness of the lines on the graphs. Statistical significance was determined using
two-way analysis of variance (ANOVA), and P < 0.05 was considered to be
significant. Control: untreated control cells.
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2.6. Statistical analyses
All data were uploaded to excel format and statistical analyses
were performed by using SPSS 16.0 version in computer via
appropriate method based on data type as parametrical or non-
parametrical.Fig. 2. Percentage changes in apoptotic, necrotic and alive K562 cells treated with 60 m
Statistical significance was determined using Student’s t test, and P < 0.05 was conside3. Results
3.1. Zoledronic acid reduced proliferation of K562 cells in a time- and
dose-dependent manner
The degree of cytotoxicity induced by zoledronic acid on human
K562 cells was assessed by XTT assay, and the results showed that
zoledronic acid decreased cell proliferation significantly in a time-
and dose-dependent manner (Fig. 1). The IC50 value of zoledronic
acid was calculated from the cytotoxicity plots, and was
determined to be 60 and 42 mM for 48 and 72 h, respectively.
3.2. Zoledronic acid-induced apoptosis in K562 cells
Significant increases were observed in apoptotic cell population
in a time-dependent manner in zoledronic acid treated K562 cells.
There were 23, 31, 34 and 34% apoptotic cell population in 24, 48, 72
and 96 h zoledronic acid exposed K562 cells (Fig. 2A). These values
were statistically significant when compared to 10% apoptotic cell
population in untreated control group (P = 0.03). Apoptotic cells
were morphologically examined under fluorescence microscopy,
and cellular changes were identified. Apoptotic cells were stained
green, whereas necrotic cells were observed in red as a result of PI
staining (Fig. 2B) and live cells were observed in blue (Fig. 2C).
3.3. Zoledronic acid decreased mRNA levels of STAT3, STAT5A, and
STAT5B genes in K562 cells in a time-dependent manner
Expression levels of STAT3, -5A and -5B genes were examined
in K562 cells treated with 60 mM of zoledronic acid by qRT-PCR.M zoledronic acid (A) and microscopic examination of dead (B) and alive (C) cells.
red to be significant.
Fig. 3. Percentage changes in mRNA levels of STAT3 (B), STAT5A (C) and STAT5B (D) genes in K562 cells exposed to 60 mM zoledronic acid at 24 h intervals over a 4-day period
(A). mRNA levels of signal transducers and activator of transcription genes were normalized to G6PDH and compared to the untreated control group. Statistical significance
was determined using ANOVA and P < 0.05 was considered to be significant.
H.D. Kiper et al. / Biomedicine & Pharmacotherapy 67 (2013) 527–532530As shown on Fig. 3A and 3B, zoledronic acid significantly
decreased the expression levels of STAT3 in K562 cells in a
time-dependent manner. There were 32, 55, 63 and 70%
decreases in mRNA levels of STAT3 gene at 24, 48, 72 and 96 h,
respectively, when compared to untreated controls and normal-
ized to G6PDH (P = 0.014) (Fig. 3A, B). The expression of STAT5A
unexpectedly increased in zoledronic acid-treated K562 cells
within the first 24 h, whereas there were 15, 31 and 85%
decreases in mRNA levels of STAT5A gene after 48, 72 and 96 h
incubation with zoledronic acid when compared to untreated
controls and normalized to G6PDH. The change in the expression
levels of STAT5A gene over the total duration of experiment was of
borderline statistical significance as a result of the discordant
values at 24 h time point (P = 0.06), but the suppression rates at
72 and 96 h time points were statistically significant as compared
to untreated controls (P = 0.001 and P < 0.001) (Fig. 3A, C). There
were 42, 47, 57 and 72% decreases in mRNA levels of STAT5B in
K562 cells treated with zoledronic acid for 24, 48, 72 and 96 h,
respectively, as compared to untreated controls and normalized
to G6PDH and the difference was statistically significant
(P = 0.02) (Fig. 3A, D).
3.4. Zoledronic acid decreased protein levels of STAT3, STAT5A, and
STAT5B genes in K562 cells in a dose-dependent manner
The protein levels of STAT3, STAT5A and STAT5B in zoledronic
acid-treated K562 cells were detected by Western blot analysis
using specific anti-STAT antibodies. Protein levels of b-actin gene
was detected as internal positive control. After alkaline phospha-
tase colorimetric reaction, protein levels were evaluated according
to the thickness and darkness of the bands. The observationsrevealed that the protein levels of STAT3, STAT5A, and STAT5B
were decreased significantly in a time-dependent manner,
especially at 72 and 96 h time points (Fig. 4A, B, C). These findings
were compatible with the results of the qRT-PCR analysis, thus the
reduction of STAT expressions in transcriptional level were
confirmed by the reduction in translational level.
4. Discussion and conclusion
Targeting the alternative downstream targets of BCR-ABL is a
rational therapeutic strategy in order to overcome the tyrosine
kinase inhibitor resistance in CML. Furthermore, to determine the
future approaches, it is certainly needed to clarify the possible
relations between the signal transduction pathways of cancer and
the potential anticancer agents. Accumulating evidence has
revealed that nitrogen-containing bisphosphonates, especially
zoledronic acid, have potent anticancer activities in a variety of
cancer cells [16,17,26–29]. The principal mechanism of apoptosis
has been postulated to be through inhibition of the mevalonate
pathway, which leads to inactivation of Ras-related proteins
[16,26]. Ras is an important downstream target of BCR-ABL, thus it
has been proposed that zoledronic acid may be a potential
antileukaemic agent. In this study, we showed that zoledronic acid
also interacts with the intracellular STAT pathway and induces
apoptosis in the leukaemic clone.
Available preclinical data have demonstrated that zoledronic
acid has antiproliferative and proapoptotic efficacy on its own, and
also acts synergistically with other cytotoxic agents [30]. The first
study that assessed the antileukaemic effects of zoledronic acid
indicated that it has potent cytotoxicity on Ph(+) leukaemia cell
lines, and also significantly augments the effects of imatinib
Fig. 4. Protein levels of STAT3 (A), STAT5A (B) and STAT5B (C) genes in response to zoledronic acid. Western blot analyses were conducted for three independent experiments.
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acid acts additively following the concurrent administration with
hydroxyurea, cytarabine and daunorubicin in various leukaemia
cell lines. However, the study performed by the same group
suggested that zoledronic acid augments the in vivo effects of
imatinib only against primary Ph(+) leukaemia cells that have not
yet acquired resistance to imatinib [24,31,32]. Nevertheless,
another striking study revealed that zoledronic acid is equally
effective in inhibiting the proliferation and clonogenicity of both
imatinib-sensitive and -resistant CML cells, regardless of their
mechanism of resistance. The same study showed that the
combination of imatinib and zoledronic acid also acts synergis-
tically in imatinib-resistant CML cells [33]. On the basis of these
preclinical studies, a phase I/II study was designed to assess the
safety and efficacy of the combination of zoledronic acid with
imatinib in 10 CML patients with a suboptimal response to
imatinib alone. Although there was no haematological toxicity, no
responses were demonstrated on the combination after 6 months
[34]. These results were explained by low plasma concentrations of
zoledronic acid, which were probably 10- to 100-fold less than the
levels required to inhibit the cell growth or induce apoptosis in
vitro, as previously reported [33]. With the support of several
studies that showed tolerable toxicity using the dose of 16 mg
administered every 28 days, it was suggested that increasing the
dose of zoledronic acid might be effective [34–36]. Further large-
scale clinical trials with escalated doses shall be designed to assess
the factual antileukemic efficacy of zoledronic acid in CML
patients.
In the first stage of our study, we examined the potential
cytotoxic and apoptotic effects of zoledronic acid on K562 CML
cells, and investigated the possible mechanisms involved in cell
death. The results of XTT cell proliferation assays revealed that
zoledronic acid decreased proliferation of K562 cells in a dose- and
time-dependent manner. Fluorescently labelled annexin-V is
widely used for the detection of apoptotic cells by measuring
the plasma membrane phosphatidylserine externalization, and is
also advantageous as it offers the possibility of detecting early
phases of apoptosis before the loss of cell membrane integrity [37].
Apoptosis analyses showed that there was a remarkable increase in
the number of apoptotic cells in zoledronic acid-treated K562 cells
in a time-dependent manner. This difference was statistically
significant when compared to untreated controls (P = 0.03) and
indicated that zoledronic acid induces apoptosis in K562 cells.
STAT pathways play a pivotal role in oncogenesis and
leukemogenesis, and thus targeting the STAT signalling pathway
appears to be an effective anticancer treatment strategy. It has
been described that constitutive activation of STAT3 and STAT5
plays a pro-oncogenic role both in acute and chronic myeloidneoplasms [38,39]. STAT5 signalling has been shown to play an
important role in the antiapoptotic activity mediated by BCR-ABL
by up-regulating the expression of the antiapoptotic gene Bcl-XL,
and it is known that imatinib mesylate also induces apoptosis by
this mechanism [40]. In the second stage of our study, we aimed to
identify the pathway(s) that play role in zoledronic acid-induced
apoptosis in K562 cells. Therefore, we investigated the mRNA and
protein levels of STAT3, -5A and -5B genes in zoledronic acid-
treated K562 cells by qRT-PCR and Western blot, respectively. The
results demonstrated that there were significant decreases in
mRNA and protein levels of STAT3 (P = 0.014), STAT5A (P < 0.001),
and STAT5B (P = 0.02) genes. Based on these results, we suggested
that STAT3, STAT5A and STAT5B may have a significant role in
zoledronic acid-induced leukaemic cell death.
In conclusion, these data indicated that zoledronic acid inhibits
cell proliferation and induces apoptosis via the STAT pathway in
K562 CML cells, and if it can be conveyed to the clinical area,
zoledronic acid may contribute to the treatment of CML as a
promising therapeutic agent. Further drug-combination studies
are needed to explore whether zoledronic acid could augment the
antileukemic effects of tyrosine kinase inhibitors by potent STAT
inhibition, and if it could be used as an appropriate approach to
overcome drug-resistance or -intolerance in CML. Furthermore, in
this study, we have shown for the first time that zoledronic acid
triggers apoptosis through inhibiting the expression of STATs in
any malignancy. This finding is important to propose that
discovery or identification of novel agents targeted to STATs
may open a new way for the treatment of different types of
haematological and solid malignancies, associated with aberrant
STAT expression.
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